Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
- Authors
- Oh, Jihoon; Oh, Jihye; Kim, Dong Wook; Youn, HyunChul; Kim, Sae-Hoon; Kim, Soo In; Chung, In Won; Wang, Kuan Shu; Kim, Minah; Paik, Jong -Woo; Koh, Min Jung; Lee, Yoosun; Choi, Seok Young; Kim, Jung-Jin
- Issue Date
- Feb-2023
- Publisher
- 대한정신약물학회
- Keywords
- KEY WORDS; Schizophrenia; Antipsychotics; Paliperidone palmitate; Clinical global impression; Personal and social performance
- Citation
- Clinical Psychopharmacology and Neuroscience, v.21, no.2, pp 126 - 134
- Pages
- 9
- Journal Title
- Clinical Psychopharmacology and Neuroscience
- Volume
- 21
- Number
- 2
- Start Page
- 126
- End Page
- 134
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22452
- DOI
- 10.9758/cpn.2023.21.1.126
- ISSN
- 1738-1088
2093-4327
- Abstract
- Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmi-tate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 +/- 18.0 vs. 61.0 +/- 14.5 [mean +/- standard deviation]; p < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71-100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 +/- 1.0 vs. 3.4 +/- 0.9; p < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p < 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social per-formance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social func-tioning of and promote return to activities of daily living in patients with schizophrenia.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Psychiatry > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22452)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.